Copyright
©The Author(s) 2023.
World J Clin Cases. Jan 26, 2023; 11(3): 566-575
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.566
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.566
Table 4 Serum anti-phospholipase A2 receptor titer and CD 19+ B-cell count during administering of Rituximab
| Patient No. | Before administering of RTX (0 mo) | Administering of RTX (3 mo) | After administering of RTX (6 mo) | |||
| Anti-PLA2R titer (RU/mL) | CD19+ B (pcs/μL) | PLA2R antibody (RU/mL) | CD19+ B (pcs/μL) | PLA2R antibody (RU/mL) | CD19+ B (pcs/μL) | |
| 1 | 1400 | 418 | 104 | 0 | Negative | 0 |
| 2 | 180 | 6 | 96 | 0 | 82 | 0 |
| 3 | 215 | 169 | 67 | 0 | 48 | 0 |
| 4 | 500 | 422 | - | - | - | - |
| 5 | 32 | 114 | 27 | 0 | 20 | 0 |
| 6 | 45 | 28 | Negative | 0 | Negative | 0 |
| 7 | 52 | 460 | 22 | 0 | 17 | 0 |
| 8 | 130 | 192 | 38 | 0 | Negative | 0 |
| 9 | 36 | 258 | 21 | 0 | Negative | 0 |
- Citation: Wang YW, Wang XH, Wang HX, Yu RH. Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience. World J Clin Cases 2023; 11(3): 566-575
- URL: https://www.wjgnet.com/2307-8960/full/v11/i3/566.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i3.566